Disposition
of Participants |
|||
|
Xanomeline High Dose |
Xanomeline Low Dose |
Placebo |
|
n |
n |
n |
Participants randomized |
84 |
84 |
86 |
Participants treated |
84 |
84 |
86 |
Participants completed |
27 |
25 |
58 |
Participants discontinued |
57 |
59 |
28 |
Discontinued reason |
|||
Adverse Event |
40 |
44 |
8 |
Death |
0 |
1 |
2 |
I/E Not Met |
2 |
0 |
1 |
Lack of Efficacy |
1 |
0 |
3 |
Lost to Follow-up |
0 |
1 |
1 |
Physician Decision |
2 |
0 |
1 |
Protocol Violation |
1 |
1 |
1 |
Sponsor Decision |
3 |
2 |
2 |
Withdrew Consent |
8 |
10 |
9 |
This is footnote |
|||
Source: [Study MK9999P001: adam-adsl] |